Mega-Merger Spinoff: Triangle Pharmaceuticals
With the downsizing following mergers, some new companies are being formed by transplanted teams of executives. A team of ex-Wellcome executives have started an HIV-focused company pursuing a business Glaxo Wellcome probably couldn’t tackle. Is this the new shape of pharmaceutical start-ups?
You may also be interested in...
Pfizer was heavily invested in immuno-oncology combinations five years ago, but following setbacks, the pipeline has shifted considerably, shaped partly by the acquisition of Array.
The possibility, which seems driven by the culture of the times, may be legally possible, but experts raised many practical concerns.
After concerns from the medtech industry that a 2017 final rule requires sponsors with knowledge of off-label use of their product to add it to their label, the US FDA is proposing to delete the confusing text.